Neurologic impairment score and electromyogram were determined at baseline and 12 months.
Serum SHBG and fT levels were determined at baseline and after first and second years of treatment.
Patient-rated wrist and hand evaluation (PRWHE) scores were determined at baseline (before arthroscopy) and one year after arthroscopy.
Glycaemic control and cardiovascular risk factors were determined at baseline and at the end of the treatment period.
Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively.
The number of EPCs, inflammatory markers, oxidative stress, and FMD were determined at baseline and 4 weeks after green tea consumption.
Blood pressure, LVMI, left atrial (LA) volumes, and diastolic function were determined at baseline and after 3, 6, 9, and 12 months of treatment.
Microsphere blood flows were determined at baseline, during occlusion, after reperfusion, and before euthanasia.
Plasma concentrations of TNF-α, IL-6, and IL-1β were determined at baseline and at 3 h after declamping.
METHODS: The concentrations of sST2 and N-terminal probrain natriuretic peptide (NT-proBNP) and a heart failure severity score (HFSS), based on Framingham criteria, were determined at baseline and 2 weeks later in 48 outpatients with decompensated hf.
Frailty, assessed according to the criteria of Fried et al. (2001), as well as depressive symptoms, assessed using the GDS-15, were determined at baseline (2003 2005) then reassessed after two (2005 2007) and four (2007 2009) years.
